Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
CEVA, Inc. Q1 2026 Earnings Call - Licensing Hits Record High as Integrated Edge AI Strategy Takes Hold
CEVA delivered a strong start to 2026, with Q1 revenues rising 11% year-over-year to $27 million and licensing revenue hitting a three-year high of $17.8 million. The company secured multiple strategi...
- Licensing revenue surged 18% year-over-year to $17.8 million, marking the strongest quarter in three years and underscoring strong pipeline execution.
- Total Q1 2026 revenues rose 11% to $27 million, with gross margins holding at 86% GAAP and 87% non-GAAP.
- CEVA secured a major Bluetooth High Data Throughput (HDT) licensing win with a leading U.S. semiconductor company, covering RF, modem software, and baseband for Bluetooth 7.
- +7 more takeaways
Repligen Corporation Q1 2026 Earnings Call - Margin Expansion Accelerates as Polymem Divestiture and China OEM Partnership Drive Strategic Shift
Repligen delivered a strong Q1 2026 with 15% reported revenue growth and 11% organic growth, driven by robust demand across analytics, chromatography, and proteins. The company raised its full-year ad...
- Q1 2026 revenue reached $194 million, representing 15% reported growth and 11% organic growth, driven by strong performance across all end markets and geographies.
- Adjusted operating margin expanded 160 basis points year-over-year to 15.4%, with adjusted EBITDA margin at 21%, reflecting disciplined cost management and favorable product mix.
- Full-year 2026 adjusted EPS guidance raised to $1.97-$2.05, up $0.04 from prior expectations, supported by margin expansion and operational efficiency gains.
- +7 more takeaways
Target Hospitality Q1 2026 Earnings Call - $2B+ Contract Win Drives Raised 2026 Outlook
Target Hospitality delivered a transitional first quarter marked by margin compression as it rapidly scales its Workforce Hospitality Solutions (WHS) segment to serve the AI-driven data center buildou...
- Secured over $2 billion in multi-year contracts since February 2025, including a new AI Infrastructure Community contract generating over $750 million in revenue over a 4-year term.
- Raised full-year 2026 revenue guidance to $370 million-$380 million and adjusted EBITDA guidance to $75 million-$85 million, up from previous expectations.
- First quarter revenue came in at approximately $73 million, with adjusted EBITDA of $10 million, as the company navigated a transitional period with elevated mobilization and construction costs.
- +7 more takeaways
Seadrill Q1 2026 Earnings Call - Raised Full-Year Guidance on Strong Operational Execution and Backlog Growth
Seadrill delivered a robust first quarter, driven by early contract commencements, higher economic utilization, and disciplined cost management. The company raised its full-year 2026 revenue and EBITD...
- Seadrill raised full-year 2026 revenue guidance to $1.43-$1.48 billion and EBITDA guidance to $370-$420 million, reflecting strong Q1 performance and early contract commencements.
- First-quarter EBITDA reached $97 million, a sequential increase of $9 million, driven by higher economic utilization and increased uptime across the fleet.
- The company added approximately $860 million to its backlog, including new contracts for the West Neptune and West Vela with LLOG (Harbour Energy) in the U.S. Gulf.
- +7 more takeaways
ARKO Petroleum Corp Q1 2026 Earnings Call - IPO-Fueled Balance Sheet Strength and Dealerization Tailwind Drive Margin Expansion
ARKO Petroleum delivered a robust first quarter, with adjusted EBITDA rising 18% year-over-year to $36.4 million, driven by disciplined margin capture and a structural shift in its business mix. The c...
- Adjusted EBITDA rose 18% year-over-year to $36.4 million, reflecting strong margin capture across segments despite fuel cost volatility.
- Net leverage dropped to 2.1 times following the IPO, with $206.7 million in proceeds used to reduce debt and strengthen the balance sheet.
- Wholesale fuel contribution increased 14.2% to $22.9 million, driven by a 2.8% rise in gallon volume and higher cents-per-gallon margins.
- +9 more takeaways
Array Technologies Q1 2026 Earnings Call - Record $2.4B Order Book Driven by New Product Momentum
Array Technologies delivered a strong Q1 2026, reporting $223M in revenue and $29M in adjusted EBITDA, with adjusted gross margins expanding to 30.7%. The company set a record order book of $2.4B, sup...
- Q1 2026 revenue hit $223 million, with adjusted gross margins expanding 620 basis points sequentially to 30.7%, driven by domestic mix, productivity gains, and one-time tariff/45X benefits.
- Adjusted EBITDA surged 157% to $29 million, while GAAP net loss narrowed to $14 million, reflecting improved operational execution and cost discipline.
- The company recorded a record $2.4 billion order book, marking its second consecutive quarter with a 2.0x book-to-bill ratio and a 1.3x trailing 12-month ratio.
- +7 more takeaways
Genpact Limited Q1 2026 Earnings Call - Agentic Revenue Nearly Doubles as Company Pivots to AI-Driven Operations
Genpact delivered a record start to fiscal 2026, with total revenue rising 6.7% year-over-year to $1.296 billion and adjusted diluted EPS jumping 16.7%. The real story is the acceleration in Advanced ...
- Total revenue grew 6.7% year-over-year to $1.296 billion, marking a record start to fiscal 2026.
- Advanced Technology Solutions revenue accelerated 24% year-over-year to $345 million, now accounting for 27% of total revenue.
- Contract values for agentic solutions nearly doubled from all of 2025, with over 50% of cumulative awarded value coming from new clients.
- +9 more takeaways
Viking Therapeutics Q1 2026 Earnings Call - Subcutaneous and Oral VK2735 Programs Advance to Phase III with $600M War Chest
Viking Therapeutics is accelerating its obesity franchise with both subcutaneous and oral formulations of its lead compound VK2735 moving into phase III registration trials. The company completed enro...
- VK2735 subcutaneous phase III VANQUISH-1 and VANQUISH-2 trials are fully enrolled, with patients randomized to weekly doses of 7.5 mg, 12.5 mg, 17.5 mg, or placebo over 78 weeks.
- Oral VK2735 formulation advances to phase III development, with initiation planned for Q4 2026 following successful phase II VENTURE oral study results showing up to 12.2% weight loss at 13 weeks.
- Maintenance dosing study expanded to eight subcutaneous cohorts testing monthly and every-other-week regimens, with results expected in Q3 2026 to inform VANQUISH extension trials.
- +7 more takeaways
Exagen Q1 2026 Earnings Call - Record Revenue Driven by ASP Expansion and Commercial Scaling
Exagen reported a record first quarter of 2026, with revenue climbing 12% year-over-year to $17.3 million, fueled by a 10% jump in testing volume and a 6% year-over-year increase in trailing twelve-mo...
- Record Q1 2026 revenue of $17.3 million, up 12% year-over-year, driven by both volume and price growth.
- Testing volume grew 10% year-over-year, outpacing the estimated 5% market growth rate for the autoimmune testing category.
- Trailing twelve-month ASP expanded 6% to $444, marking the 12th consecutive quarter of ASP growth and smoothing out quarterly variability.
- +7 more takeaways
Heron Therapeutics Q1 2026 Earnings Call - Weather Headwinds Mask Strong Commercial Momentum and Pricing Discipline
Heron Therapeutics reported Q1 2026 net sales of $34.7 million, missing short-term targets due to two weeks of severe winter weather that disrupted elective surgeries and compounded typical seasonal s...
- Q1 2026 net sales totaled $34.7 million, below plan due to two weeks of severe winter weather that disrupted elective surgeries and compounded typical seasonal softness.
- March net sales exceeded $15 million, signaling a strong sequential recovery and reinforcing confidence in full-year 2026 guidance of $173 million to $183 million in net product sales.
- Growth margins came in at 69%, temporarily depressed by a secondary CINVANTI supplier contract; management expects normalization to the mid-70s range as the secondary inventory winds down over the next two quarters.
- +7 more takeaways